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at 42.18% compared to 25.91% of LLD (p < 0.0001). Bleeding,
readmission, and mortality were similar (p = NS). Risk-adjusted
logistic regression also found no evidence for better outcome 
in patients given HLD of clopidogrel. CONCLUSIONS: Using
time-stamp data, this large study retrospectively investigated
effects of HLD clopidogrel in usual care setting. Patients receiv-
ing HLD did not experience better outcome. If providers tend to
select HLD to treat high-risk patients in practice, an underlying
dose-outcome bias would exist in the data. It is unclear how
much of the bias is mitigated by higher dosing in the usual care
setting. More research is needed.
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OBJECTIVE: To review the existing evidence of the economic
impact of contrast echocardiography (CE) in the diagnosis and
management of patients with suspected or known coronary
artery disease (CAD). METHODS: A systematic search was
undertaken to identify studies that provided empirical evidence
of the cost-effectiveness of CE relative to an alternative diag-
nostic modality. Findings and study methodologies were
reviewed and suggestions for further research were offered.
RESULTS: Six studies were identiﬁed, including one conference
abstract and one unpublished study. In four studies of patients
with sub-optimal un-enhanced echocardiogaphic images, CE was
reported to reduce the average cost to obtain a diagnosis by
17–64% compared with a second-line nuclear imaging (SPECT)
test. However, these studies did not include the impact of poten-
tial differences in diagnostic accuracy between tests. A ﬁfth study
reported that compared with trans-oesophageal echocardiogra-
phy CE resulted in similar yield of accurate diagnoses at a sub-
stantial reduction in costs for determination of regional and
global ventricular function in ‘technically difﬁcult to image’
patients. In a sixth study in patients with an intermediate risk
for CAD, the average cost to identify CAD was lowest when
SPECT Tc-99m or CE ($267 and $355 per case detected, respec-
tively) and highest when exercise electrocardiography ($1320 per
case detected) was used as the ﬁrst-line test. CONCLUSIONS:
The results support the cost-effectiveness of CE compared with
nuclear imaging in patients with a sub-optimal un-enhanced
image, and potentially in other patient sub-groups such as those
with an intermediate risk of CAD. However, more comprehen-
sive economic analyses incorporating diagnostic accuracy and its
implications for patient management are required before these
results can be considered conclusive. More research is also
needed to assess the economic impact of myocardial contrast
echocardiography (MCE) in its wider applications in the man-
agement of CAD patients, such as the assessment of myocardial
viability.
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OBJECTIVES: The efﬁcacy of platelet inhibition with clopido-
grel for patients (pts) with non-ST-elevation acute coronary syn-
dromes was demonstrated in CURE and PCI-CURE trials. The
purpose of present analysis is to estimate the long-term cost-
effectiveness of clopidogrel in Poland, using clinical outcomes
and resource utilization from CURE and in PCI-CURE.
METHODS: Costs of hospitalizations and studied drugs were
calculated based on resource utilization collected in case report
form for all pts in CURE (clopidogrel, n = 6259, placebo, n =
6303) and in the subgroup of PCI-CURE pts (clopidogrel/n =
1313, placebo/n = 1345). Comedications were not included in
the economic analyses as drug utilization was similar in clopi-
dogrel and placebo group. Unit costs were calculated using drugs
retail prices and medical procedures tariffs contracted by
National Health Found. Because of lack of sufﬁcient Polish epi-
demiological data two different sources (Framingham and
Saskatchewan databases) were used to evaluate the lost life
expectancy associated with death, MI and stroke. A discount rate
of 3% was applied. Results are expressed in cost per Life Year
Saved. RESULTS: Total cost per pt was higher in the clopidogrel
arm for CURE and PCI-CURE (+€463 and +€454) respectively.
The estimated number of LYS with clopidogrel for CURE pts
was 69.9 per 1000pts treated using Framingham and 68.2 using
Saskatchewan data. Corresponding values for PCI-CURE were
69.8 per 1000 patients with Framingham and 88.5 with
Saskatchewan data. The cost per LYS for clopidogrel versus
placebo for CURE pts was €6624 with Framingham and €6789
with Saskatchewan database. For PCI-CURE pts these ﬁgures
were €6504 and €5130 respectively. CONCLUSION: Based on
the clinical ﬁndings of CURE and PCI-CURE trials clopidogrel
appears to be cost-effective in Poland. Although results obtained
from two different sources of survival data are consistent, the
interpretation of present ﬁndings requires further adjustment to
Polish epidemiological settings.
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OBJECTIVES: Low-dose Aspirin is standard care in patients
with cardiovascular disease (CVD). In primary prevention the
use of Aspirin is not fully established although meta-analyses and
guidelines support its use in persons at increased CVD risk. This
study assessed the health economic consequences of the use of
low-dose Aspirin in the primary prevention of CVD in the UK,
Germany, Spain and Italy. METHODS: Based on results reported
in two meta-analyses, a Markov model was developed to predict
the cost-effectiveness of Aspirin in the primary prevention of
CVD. Different time horizons (1 to 10 years), 1-year cycles and
direct costs from the health care payer’s perspective (2003) were
used. Effects were expressed in Life-Years (LY) and QALY. Utility
data (TTO) were obtained from published data. Country speciﬁc
discounting was applied. RESULTS: For patients with an annual
risk of coronary heart disease (CHD) of 1.5%, the model results
in average savings with low-dose aspirin after 10 years of €201
[95%CI €81–€331], €281 [95%CI €141–€422], €797 [95%CI
€301–€1331] and €427 [95%CI €122–731] per patient in the
UK, Germany, Spain and Italy, respectively. Although the savings
in the ﬁrst year are modest (on average €10-€20), from the
second year on they are signiﬁcant in all countries. Sensitivity
analysis showed the results robustness. The number of LY and
QALY gained with aspirin were respectively 0.2 and 0.4 years 
in the four countries. Monte Carlo analysis showed aspirin-
